NASD · Healthcare · Drug Manufacturers - Specialty & Generic · Canada
InMed Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
InMed Pharmaceuticals Inc develops small molecule drug candidates that act as signaling ligands for CB1 and CB2 receptors. The company's current product candidates target Alzheimer's disease, dry age-related macular degeneration, and epidermolysis bullosa. Following its wind-down of commercial operations, the company conducts preclinical research on these therapeutic candidates.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the InMed Pharmaceuticals Inc stock.
Overvalued: intrinsic value $0.13 per share, market price $1.60, margin of safety -1118.0% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $0.13; the price of $1.60 is 1118% above that value.
All 84 Drug Manufacturers - Specialty & Generic stocks
34 more in this industry show a wider margin of safety.
INM is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $0.13; the price of $1.60 is 1118% above that value.
$0.13 per share (as of the 2026-10-30 close), against a market price of $1.60. That is a margin of safety of -1118.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.